List All Pancreatic Cancer Trials

Pancreatic Cancer


PEGPH20 for Stage IV Untreated Pancreatic Cancer (2687)
A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase)Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer

Investigator: Sunil R. Hingorani, MD;   Conditions: Metastatic Pancreatic Cancer;    Status: Closed;   Study ID: NCT01839487

Modified FOLFIRINOX + PEGPH20 for Pancreatic Cancer (S1313)
S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma

Investigator: Gabriela Chiorean, MD;   Conditions: Pancreatic Cancer;    Status: Pending;   Study ID: NCT01959139

Afatinib Dimaleate and Capecitabine for Solid Tumors, Pancreatic Cancer or Biliary Cancer (9078)
Phase I/IB Multi-Center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination with Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers

Investigator: Gabriela Chiorean. MD;   Conditions: Bile Duct Carcinoma, Recurrent Pancreatic Carcinoma, Solid Neoplasm, Stage III Pancreatic Cancer, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT02451553

PEGPH20 + Nab-Paclitaxel Plus Gemcitabine for Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Investigator: Andrew L. Coveler, MD;   Conditions: Pancreatic Ductal Adenocarcinoma;    Status: Recruiting;   Study ID: NCT02715804